AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in ...

Daiichi Sankyo recognizes the U.S. sales of Enhertu while AstraZeneca records its share of gross profit margin from Enhertu sales under Alliance revenues. In 2023, Enhertu generated around $1 ...

The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate or ADC discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Continued approval of this tumor agnostic indication is contingent upon verification of clinical benefit in a confirmatory trial. The Food and Drug Administration (FDA) has granted accelerated ...

The drug benefited people whose tumors have “ultralow” levels of HER2 protein, a result that could extend its reach in HER2-positive breast cancer.

AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself. After spearheading the new HER2-low category in breast cancer treatment, Enhertu has shown it could be ...

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of ...

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca ’s Enhertu for adults with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive ...

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours Enhertu now has five approved indications ...